Gerd R. Burmester, ACR 2021: Long-term Sarilumab Treatment for Active Rheumatoid Arthritis
We were delighted to speak with Professor Gerd R. Burmester (Charité – Universitätsmedizin Berlin, Berlin, Germany) around the open label extension studies of sarilumab for the treatment of active rheumatoid arthritis (EXTEND: NCT01146652 and MONARCH: NCT02332590).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies.‘ (ABSTRACT NUMBER: 1690) was presented at the ACR Convergence, 3-9 November 2021.
- In which patients with rheumatoid arthritis (RA) is sarilumab indicated? (0:15)
- What were the aims and design of the analysis of the EXTEND and MONARCH studies? (0:41)
- What were the efficacy and safety findings of this analysis? (1:41)
- How did these findings compare with other studies? (2:48)
- What can we conclude about the long-term efficacy and safety of sarilumab in RA and what questions remain unanswered? (3:20)
Disclosures: Gerd R. Burmester discloses honoraria for lectures and consulting for Sanofi and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!